{
  "docId": "019de073-a4f9-77e5-8cbf-a98a0ec20f41",
  "docSlug": "527bf315fca9a14279ec523dc4665564",
  "documentTitle": "Athira Pharma | Results Presentation Deck | 11 slides",
  "authorId": "athira-pharma",
  "authorName": "Athira Pharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 11,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "key_takeaways",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "The chart shows a significant p-value of 0.018 for NfL reduction. The study design is noted as randomized, double-blind, placebo-controlled, and parallel-group.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-a4f9-77e5-8cbf-a98a0ec20f41/5",
  "deckHref": "/decks/019de073-a4f9-77e5-8cbf-a98a0ec20f41",
  "deckJsonHref": "/decks/019de073-a4f9-77e5-8cbf-a98a0ec20f41.json",
  "deckAnchorHref": "/decks/019de073-a4f9-77e5-8cbf-a98a0ec20f41#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.4,
        "x": 0.55,
        "y": 0.2
      },
      "kind": "chart",
      "text": "NfL at week 26 (fosgonimeton without background therapy)",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0f47ae92-dd04-4814-955b-424077fd89ec",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.5,
        "x": 0.03,
        "y": 0.2
      },
      "kind": "list",
      "text": "Favorable safety and tolerability profile. Fosgonimeton signals without background therapy compared to placebo: Reduced ERP P300 latency (n.s.), Improved cognition (ADAS-Cog11, n.s.), Improved function (ADCS-ADL23, n.s.), Significant NfL improvement.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0ea804bf-4d07-4a6a-ad9d-c45de75f9f17",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.03,
        "y": 0.75
      },
      "kind": "paragraph",
      "text": "ACT-AD was a similar study design to LIFT-AD to help inform larger LIFT-AD. Both are randomized, double-blind, placebo-controlled, parallel-group studies of fosgonimeton for patients with mild-to-moderate Alzheimer's disease.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ccc565d4-1bab-4167-9ccd-0182c8393656",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.5,
        "x": 0.12,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "ADAS-Cog11, Alzheimer's Disease Assessment Scale-Cognitive Subscale; ADCS-ADL23, Alzheimer's Disease Cooperative Study-Activities of Daily Living; ERP, event related potential; NfL, neurofilament light chain. Data presented are least squares mean ± SE. Data shown as mean NfL concentration (SEM).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e2a34607-08bf-4971-9cbc-757839c72da9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "Summary of Phase 2 ACT-AD Study Results",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7076ee48-6b7c-416a-8b25-9bc66672efa0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.8,
        "x": 0.03,
        "y": 0.12
      },
      "kind": "title",
      "text": "EXPLORATORY STUDY TO INFORM LARGER LIFT-AD IN PATIENTS WITHOUT BACKGROUND THERAPY",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "467b064b-d736-4a72-bead-15addbfb0595",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 11,
      "from": 4,
      "beatId": "ec20a1da-004a-4f5b-ac24-cdc67eafb0cd",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Fosgonimeton shows promise as a new potential therapy for Alzheimer's disease",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 11,
      "from": 4,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "8b9b785b-4f0f-46be-8af5-f2f0d1f429d0",
      "evidence": "Clear presentation of study results and next steps",
      "position": 1,
      "objective": "What are the key takeaways from the Phase 2/3 LIFT-AD study?",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.7,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}